PD-L1 Staining Immune and Tumor Cells in a Triple-Negative Breast Cancer (TNBC) case

Join Agilent CDx Pathology Manager, Ed Manna, as he walks through a Triple-Negative Breast Cancer (TNBC) case stained with PD-L1 IHC 22C3 pharmDx. This video covers the differences of immune cell staining and tumor cell staining, and how to best assess the Combined Positive Score (CPS) for cases with this type of heterogeneous staining. ​

The Spotlight Video Series walks you through CPS principles and scoring strategies for cases stained with PD-L1 IHC 22C3 pharmDx. Through this engaging series, Agilent PD-L1 experts will help you to confidently:​

• Evaluate H&E, NCR, and PD-L1 slides for adequacy ​
• Understand inclusion/exclusion criteria and other core principles of Combined Positive Score (CPS)​
• Determine the best approaches for scoring cases based on specific characteristics and features​
• Navigate challenging morphology and staining characteristics​

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.​D0113759_1.00